Top

Published in:

01-08-2014 | Neurology and Preclinical Neurological Studies - Review Article

The relevance of dopaminergic level in nocturnal disability in Parkinson’s disease: implications of continuous dopaminergic stimulation at night to treat the symptoms

Authors: Fabrizio Stocchi, Paola Stirpe

Published in: Journal of Neural Transmission | Special Issue 1/2014

Abstract

Sleep problems are an under-emphasized cause of disability in Parkinson’s disease (PD). Difficult sleep maintenance (light and fragmented sleep) and difficulties in initiating sleep are often the earliest and the most frequent symptoms observed in PD patients. In fluctuating patients, nocturnal akinesia, dystonia, painful cramps, and parasomnias may aggravate nocturnal problems. Treatment of sleep problems can be complex and challenging for the physicians. Dopaminergic treatment may improve some of the nocturnal symptoms in PD. In this paper, the effect of drugs and technique that ensure a more continuous delivery of dopaminergic drugs on sleep problems in PD is reviewed.

Baas HK, Schueler P (2001) Efficacy of cabergoline in long-term use: results of three observational studies in 1500 patients with Parkinson’s disease. Eur Neurol 46(Suppl 1):18–23PubMedCrossRef

Barone P, Amboni M, Vitale C, Bonavita V (2004) Treatment of nocturnal disturbances and excessive daytime sleepiness in Parkinson’s disease. Neurology 63(8 Suppl 3):S35–S38PubMedCrossRef

Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP et al (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24:1641–1649PubMedCrossRef

Chaudhuri KR, Clough C (1998) Subcutaneous apomorphine in Parkinson’s disease. BMJ 316(7132):641PubMedCentralPubMedCrossRef

Chaudhuri KR, Logishetty K (2009) Dopamine receptor agonists and sleep disturbances in Parkinson’s disease. Parkinsonism Relat Disord 15(Suppl 4):S101–S104PubMedCrossRef

Christmas TJ, Kempster PA, Chapple CR, Frankel JP, Lees AJ, Stern GM, Milroy EJ (1988) Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 2(8626–8627):1451–1453PubMedCrossRef

Factor SA, Weiner WJ (1998) Sleep benefit in Parkinson’s disease. Neurology 50(5):1514–1515PubMedCrossRef

Factor S, McAlarney T, Sanchez-Ramos JR, Weiner WJ (1990) Sleep disorders and sleep effect in Parkinson’s disease. Mov Disord 5:280–285PubMedCrossRef

Fernandez HH, Odin P (2011) Levodopa–carbidopa intestinal gel for treatment of advanced Parkinson’s disease. Curr Med Res Opin 27(5):907–919PubMedCrossRef

Friedman A (1980) Sleep pattern in Parkinson’s disease. Acta Med Pol 21(2):193–199PubMed

Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S (1999) Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 10(52(9)):1908–1910CrossRef

Garcia Ruiz PJ (2006) Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson’s disease. Mov Disord 21(5):727–728PubMedCrossRef

Ghys L, Surmann E, Whitesides J, Boroojerdi B (2011) Effect of rotigotine on sleep and quality of life in Parkinson’s disease patients: post hoc analysis of RECOVER patients who were symptomatic at baseline. Expert Opin Pharmacother 12(13):1985–1998PubMedCrossRef

Giladi N, Fichtner A, Poewe W, Boroojerdi B (2010) Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson’s disease. J Neural Transm 117(12):1395–1399PubMedCrossRef

Högl B, Rothdach A, Wetter TC, Trenkwalder C (2003) The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson’s disease. Neuropsychopharmacology 28(10):1866–1870PubMedCrossRef

Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, Fox K, Mancini F, Canesi M, Odin P, Chaudhuri KR (2009) Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 24(10):1468–1474PubMedCrossRef

Jansen EN, Meerwaldtt JD (1990) Madopar HBS in nocturnal symptoms of Parkinson’s disease. Adv Neurol 53:527–531PubMed

Jellinger KA (1991) Pathology of Parkinson’s disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 14(3):153–197PubMedCrossRef

Johns MV (1993) Daytime sleepiness, snoring and obstructive sleep apnea. The Epworth Sleepiness Scale. Chest 103:30–36PubMedCrossRef

Kales AN, Phang JM (1971) The effect of divided calcium intake on calcium metabolism. J Clin Endocrinol Metab 32(1):83–87PubMedCrossRef

Kelly DD (1991) Disorders of sleep and consciousness. In: Kandel ER, Schwartz JH, Jessel TM (eds) Principles of neuronal science. Appleton and Lange, Norwalk, pp 805–819

Leeman AL, O’Neill CJ, Nicholson PW, Deshmukh AA, Denham MJ, Royston JP, Dobbs RJ, Dobbs SM (1987) Parkinson’s disease in the elderly: response to an optimal spacing of night time dosing with levodopa. Br J Clin Pharmacol 24(5):637–643PubMedCentralPubMedCrossRef

Lees AJ, Blackburn NA, Campbell VL (1988) The nighttime problems of Parkinson’s disease. Clin Neuropharm 11:512–519CrossRef

Martinez-Martin P, Jeukens-Visser M, Lyons KE, Rodriguez-Blazquez C, Selai C, Siderowf A, Welsh M, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG, Schrag A (2011) Health-related quality-of-life scales in Parkinson’s disease: critique and recommendations. Mov Disord 26(13):2371–2380PubMedCrossRef

Pahwa R, Busenbark K, Huber SJ, Michalek D, Hubble JP, Koller WC (1993) Clinical experience with controlled-release carbidopa/levodopa in Parkinson’s disease. Neurology 43(4):677–681PubMedCrossRef

Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, Elmer LW, Truong DD, Earl NL, EASE-PD Adjunct Study Investigators (2007) Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 68(14):1108–1115PubMedCrossRef

Pastor P, Tolosa E (2003) Cabergoline in the treatment of Parkinson’s disease. Neurologia 18(4):202–209PubMed

Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B, SP 515 Investigators (2007) Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 6(6):513–520PubMedCrossRef

Priano L, Albani G, Brioschi A, Guastamacchia G, Calderoni S, Lopiano L, Rizzone M, Cavalli R, Gasco MR, Fraschini F, Bergamasco B, Mauro A (2003) Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment. Neurol Sci 24(3):207–208PubMedCrossRef

Ray Chaudhuri K, Martinez-Martin P, Rolfe KA, Cooper J, Rockett CB, Giorgi L, Ondo WG (2012) Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson’s disease. Eur J Neurol 19:105–113PubMedCrossRef

Reichmann H, Cooper J, Rolfe K, Martinez-Martin P (2011) Sleep duration and “on’ time during different periods of the day and night in patients with advanced Parkinson’s disease receiving adjunctive ropinirole prolonged release. Parkinsons Dis 2011:354760PubMedCentralPubMed

Reuter I, Ellis CM, Ray Chaudhuri K (1999) Nocturnal subcutaneous apomorphine infusion in Parkinson’s disease and restless legs syndrome. Acta Neurol Scand 100(3):163–167PubMedCrossRef

Rinne UK, Larsen JP, Siden A, Worm-Petersen J (1998) Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 51(5):1309–1314PubMedCrossRef

Sanford M, Scott LJ (2011) Rotigotine transdermal patch: a review of its use in the treatment of Parkinson’s disease. CNS Drugs 25(8):699–719PubMedCrossRef

Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C (2011) The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 26(Suppl 3):S42–S80PubMedCentralPubMedCrossRef

Stocchi F, Destée A (1998) Co-administration of ropinirole and domperidone during rapid dose escalation of the dopamine agonist. Parkinsonism Relat Disord 4(4):183–188PubMedCrossRef

Stocchi F, Ruggieri S, Baronti F, Bellantuono P, Brughita G, Antonini A, Bravi D, Agnoli A (1987) On-off phenomena in Parkinson’s disease. Continuous dopaminergic stimulation. Clin Ter 122(2):83–88PubMed

Stocchi F et al (2000) Sleep disturbances in Parkinson’s disease. Eur J Neurol 7(Suppl. 4):21–25

Stocchi F, Vacca L, Valente M, Ruggieri S (2001) Sleep disorders in Parkinson’s disease. Adv Neurol 86:289–293PubMed

Tandberg E, Larsen JP, Karlsen K (1999) Excessive daytime sleepiness and sleep benefit in Parkinson’s disease: a community-based study. Mov Disord 14:922–927PubMedCrossRef

Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P, Hill D, Anderson T, Myllyla V, Kassubek J, Steiger M, Zucconi M, Tolosa E, Poewe W, Surmann E, Whitesides J, Boroojerdi B, Chaudhuri KR, Recover Study Group (2011) Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 26(1):90–99PubMedCentralPubMedCrossRef

Tribl GG, Sycha T, Kotzailias N, Zeitlhofer J, Auff E (2005) Apomorphine in idiopathic restless legs syndrome: an exploratory study. J Neurol Neurosurg Psychiatry 76(2):181–185PubMedCentralPubMedCrossRef

Van den Kerchove M, Jacquy J, Gonce M, De Deyn PP (1993) Sustained-release levodopa in parkinsonian patients with nocturnal disabilities. Acta Neurol Belg 93(1):32–39PubMed

Wailke S, Herzog J, Witt K, Deuschl G, Volkmann J (2011) Effect of controlled-release levodopa on the microstructure of sleep in Parkinson’s disease. Eur J Neurol 18(4):590–596PubMedCrossRef

Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 356(1):39–46PubMedCrossRef

Title: The relevance of dopaminergic level in nocturnal disability in Parkinson’s disease: implications of continuous dopaminergic stimulation at night to treat the symptoms
Authors: Fabrizio Stocchi
Paola Stirpe
Publication date: 01-08-2014
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue Special Issue 1/2014
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-014-1259-2

At a glance: The STEP trials

Springer Medicine

The relevance of dopaminergic level in nocturnal disability in Parkinson’s disease: implications of continuous dopaminergic stimulation at night to treat the symptoms

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 1/2014

The impact of the nocturnal disabilities of Parkinson’s disease on caregivers’ burden: implications for interventions

Nocturnal manifestations of Parkinson’s disease and atypical Parkinsonism

Nocturnal journey of body and mind in Parkinson’s disease: the manifestations, risk factors and their relationship to daytime symptoms. Evidence from the NIGHT-PD study

Nocturnal manifestations of atypical and vascular parkinsonism: How do they differ from Parkinson’s disease?

Sleep/wake problems in Parkinson’s disease: pathophysiology and clinicopathologic correlations

Rating scales and questionnaires for assessment of sleep disorders in Parkinson’s disease: what they inform about?